The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Cabozantinib in Combination With Atezolizumab versus Sorafenib in Treatment-Naive Advanced Hepatocellular Carcinoma: COSMIC-312 Phase III Study Design
Futute Oncol. 2020 Jun 3. doi: 10.2217/fon-2020-0283. Online ahead of print.
Robin Kate Kelley1, Jennifer W Oliver2, Saswati Hazra2, Fawzi Benzaghou3, Thomas Yau4, Ann-Lii Cheng5, Lorenza Rimassa67
Author information
1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA.
2Exelixis, Inc., Alameda, CA, USA.
3Ipsen Bioscience, Inc., Cambridge, MA, USA.
4University of Hong Kong, Hong Kong, China.
5National Taiwan University College of Medicine, Taipei, Taiwan.
6Medical Oncology & Hematology Unit, Humanitas Cancer Center, Humanitas Clinical & Research Center, IRCCS, Rozzano, Milan, Italy.
7Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Free article
Abstract
Cabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM (TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and angiogenesis, cabozantinib targets promote an immune-suppressive microenvironment. Cabozantinib is approved as single-agent therapy for patients with advanced hepatocellular carcinoma who received prior sorafenib. Owing to its antitumor and immunomodulatory properties, cabozantinib is being developed in combination with immune checkpoint inhibitors. Early studies of these combinations have shown promising antitumor activity and tolerability in patients with solid tumors. Here, we describe the rationale and design of COSMIC-312, a Phase III study evaluating the safety and efficacy of cabozantinib in combination with atezolizumab (anti-PD-L1 monoclonal antibody) versussorafenib for treatment-naive patients with advanced hepatocellular carcinoma. Clinical Trial Registration: NCT03755791 (ClinicalTrials.gov).